^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272

Excerpt:
Consistent with previous reports, H3255 (EGFR L858R) and HCC827 (EGFR E746_A750del) were sensitive to erlotinib treatment ( 15, 16), with IC50 values of 0.031 and 0.003 μmol/L, respectively ( Fig. 1A). Both cell lines were also extremely sensitive to HKI-272 treatment with IC50 values of 0.0049 and 0.039 μmol/L, respectively. 
DOI:
10.1158/0008-5472.CAN-06-0971